Introduction: History of psoriasis and psoriasis therapy

  • Alissa Cowden
  • Abby S. Van Voorhees
Part of the Milestones in Drug Therapy book series (MDT)


This chronicle of psoriasis begins in ancient times when psoriasis, leprosy, and other inflammatory skin disorders were thought to be the same condition. The identification of psoriasis as a distinct entity did not occur until the 19th century, when clinical descriptions distinguished it from other cutaneous disorders. Histopathologic descriptions in the 1960s and 1970s shed some light on the pathophysiology of psoriasis, but many aspects of the disease remain unknown to this day. As Bechet expressed, “Psoriasis is an antidote for dermatologists’ ego” [1].


Psoriatic Lesion Seborrheic Dermatitis PUVA Therapy Folic Acid Antagonist Psoriasis Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bechet PE (1936) Psoriasis, a brief historical review. Arch Dermatol Syph 33: 327–334Google Scholar
  2. 2.
    Hebra F (1868) On disease of the skin. New Sydenham Society, LondonGoogle Scholar
  3. 3.
    Fox H (1915) Dermatology of the ancients. JAMA 65: 469Google Scholar
  4. 4.
    Sutton RL (1986) Sixteenth century physician and his methods mercurialis on diseases of the skin. The Lowell Press, Kansas City, MOGoogle Scholar
  5. 5.
    Pusey WA (1933) The history of dermatology. Charles C Thomas, Springfield, ILGoogle Scholar
  6. 6.
    Glickman FS (1986) Lepra, psora, psoriasis. J Am Acad Dermatol 14(5 Pt 1): 863–866PubMedGoogle Scholar
  7. 7.
    Celsus AC (1837) De re medica. East Portwine, LondonGoogle Scholar
  8. 8.
    Willan, R (1809) On Cutaneous Diseases. Kimber and Conrad, PhiladelphiaGoogle Scholar
  9. 9.
    Rayer P (1835) Treatises on diseases of the skin. 2nd ed. J.B. Bailliere, LondonGoogle Scholar
  10. 10.
    Gibert CM (1840) Traite pratique des maladies speciales de la peau. 2nd ed. Germer-Bailliere, ParisGoogle Scholar
  11. 11.
    Wilson E (1863) Diseases of the skin. Blanchchard and Lea, PhiladelphiaGoogle Scholar
  12. 12.
    Fox T (1871) Skin diseases: Their description, pathology, diagnosis, and treatment. William Wood and Co, New YorkGoogle Scholar
  13. 13.
    Milton JL (1872) Diseases of the skin. Robert Hardwicke, LondonGoogle Scholar
  14. 14.
    Crissey JT, Parish LC, Shelley WB (1981) The dermatology and syphilology of the nineteenth century. Praiger Publishers, New YorkGoogle Scholar
  15. 15.
    Hebra on F, Kaposi M (1876) Lehrbuch der Hautkrankheiten. Ferdinanand Euke, StuttgartGoogle Scholar
  16. 16.
    Fry L (1988) Psoriasis. Br J Dermatol 119(4): 445–461PubMedCrossRefGoogle Scholar
  17. 17.
    Farber EM (1982) Historical Commentary. In: EM Farber, AJ Cox, L Nall, PH Jacobs (eds): Psoriasis: proceedings of the Third International Symposium, Stanford University, 1981. Third ed. Grune and Stratton, New York, 7–11Google Scholar
  18. 18.
    Köbner H (1876) Zur Aetiologie der Psoriasis. Vjschr Dermatol 3: 559–561Google Scholar
  19. 19.
    von Zumbusch LR (1910) Psoriasis und pustuloses exanthem. Archives of Dermatology and Syphiliology 99: 335–346CrossRefGoogle Scholar
  20. 20.
    Woronoff DL (1926) Die peripheren Veränderungen der Haut um die Effloreszenzen der Psoriasis vulgaris und Syphilis corymbosa. Dermatologische Wochenschrift 82: 249–257Google Scholar
  21. 21.
    VanScott EJ, Ekel TM (1963) Kinetics of hyperplasia in psoriasis. Arch Dermatol 88: 373–381PubMedGoogle Scholar
  22. 22.
    Weinstein GD, Van Scott EJ (1966) Turnover time of human normal and psoriatic epidermis by autoradiographic analysis. J Inves Dermatol 45: 561–567Google Scholar
  23. 23.
    Gubner R (1951) Effect of aminopterin on epithelial tissues. AMA Arch Derm Syphilol 64(6): 688–699PubMedGoogle Scholar
  24. 24.
    Mueller W, Herrmann B (1979) Cyclosporin A for psoriasis. N Engl J Med 301(10): 555PubMedGoogle Scholar
  25. 25.
    Bjerke JR, Krogh HK, Matre R (1978) Characterization of mononuclear cell infiltrates in psoriatic lesions. J Invest Dermatol 71(5): 340–343PubMedCrossRefGoogle Scholar
  26. 26.
    Baker BS, Swain AF, Fry L, Valdimarsson H (1984) Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 110(5): 555–564PubMedCrossRefGoogle Scholar
  27. 27.
    Schon MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352(18): 1899–1912PubMedCrossRefGoogle Scholar
  28. 28.
    Girdlestone T (1806) Observations on the effects of Dr. Fowler’s mineral solution in lepra and other diseases. Med Phys J London 15: 298–301Google Scholar
  29. 29.
    Farber EM (1992) History of the treatment of psoriasis. J Am Acad Dermatol 27(4): 640–645PubMedCrossRefGoogle Scholar
  30. 30.
    Duhring LA (1876) Atlas of skin diseases. JB Lippincot and Co, PhiladelphiaGoogle Scholar
  31. 31.
    Squire B (1876) Treatment of psoriasis by an ointment of chrysophanic acid. BMJ 819–920Google Scholar
  32. 32.
    Unna PG (1916) Cignolin als Heilmittel der Psoriasis. Dermatologische Wochenschrift 6: 116–137, 151–163, 175–183Google Scholar
  33. 33.
    Hjorth N, Norgaard M (1991) Tars. In: HH Roenigk, HL Maibach (eds): Psoriasis. Marcel Dekker, New York, 473–479Google Scholar
  34. 34.
    Squire B (1878) Atlas of skin diseases. JandA Churchill, LondonGoogle Scholar
  35. 35.
    Goeckerman WH (1925) The treatment of psoriasis. Northwest Med 25: 229–231Google Scholar
  36. 36.
    Ingram JT (1953) The approach to psoriasis. BMJ 2: 591–593PubMedCrossRefGoogle Scholar
  37. 37.
    Lundberg IE, Grundtman C, Larsson E, Klareskog L (2004) Corticosteroids — from an idea to clinical use. Best Pract Res Clin Rheumatol 18(1): 7–19PubMedCrossRefGoogle Scholar
  38. 38.
    Hench PS, Kendall EC, Slocumb CH, Polley HF (1950) Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Med Interna 85(4): 545–666PubMedGoogle Scholar
  39. 39.
    Sulzberger MB, Witten VH (1952) The effect of topially applied compound F in selected dermatoses. J Invest Dermatol 19: 101–102PubMedGoogle Scholar
  40. 40.
    Farber S, Diamond L, Mercer R, Sylvester R, Wolff V (1946) Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-amethopteroylglutamic acid (aminopterin). N Engl J Med 238: 787–793Google Scholar
  41. 41.
    Edmundson WF, Guy WB (1958) Treatment of psoriasis with folic acid antagonists. AMA Arch Derm 78(2): 200–203PubMedGoogle Scholar
  42. 42.
    Roenigk HH Jr, Maibach HI, Weinstein GD (1973) Use of methotrexate in psoriasis. Arch Dermatol 105(3): 363–365CrossRefGoogle Scholar
  43. 43.
    Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA (1974) Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 291(23): 1207–1211PubMedGoogle Scholar
  44. 44.
    Benedetto AV (1977) The psoralens: An historical perspective. Cutis 20: 469–471PubMedGoogle Scholar
  45. 45.
    Melski JW, Tanenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL (1977) Oral methoxsalen photochemotherapy for the treatment of psoriasis: A cooperative clinical trial. J Invest Dermatol 68(6): 328–335PubMedCrossRefGoogle Scholar
  46. 46.
    Fischer T, Alsins J (1976) Treatment of psoriasis with trioxsalen baths and dysprosium lamps. Acta Derm Venereol 383–390Google Scholar
  47. 47.
    Parrish JA, Jaenicke KF (1981) Action spectrum for phototherapy of psoriasis. J Invest Dermatol 76: 359–361PubMedCrossRefGoogle Scholar
  48. 48.
    Green C, Ferguson J, Lakshmipathi T, Johnson BE (1988) 311 nm UVB phototherapy — an effective treatment for psoriasis. Br J Dermatol 119(6): 691–696PubMedCrossRefGoogle Scholar
  49. 49.
    Picot E, Meunier L, Picot-Debeze MC, Peyron JL, Meynadier J (1992) Treatment of psoriasis with a 311-nm UVB lamp. Br J Dermatol 127(5): 509–512PubMedCrossRefGoogle Scholar
  50. 50.
    Wolbach SB, Howe PR (1925) Tisse changes following deprivation of fat-solbe A-vitamin. J Experimental Med 42: 753–778CrossRefGoogle Scholar
  51. 51.
    Stuttgen G (1962) Zur Lokalbehandlung von Keratosen mit Vitamin A-Säure. Dermatologica 124: 65–80CrossRefGoogle Scholar
  52. 52.
    Tsambaos D, Orfanos CE (1981) Chemotherapy of psoriasis and other skin disorders with oral retinoids. Pharmacol Ther 14(3): 355–374PubMedCrossRefGoogle Scholar
  53. 53.
    Ward A, Brogden RN, Heel RC, Speight TM, Avery GS (1984) Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs 28(1): 6–37PubMedCrossRefGoogle Scholar
  54. 54.
    Ellis CN, Voorhees JJ (1987) Etretinate therapy. J Am Acad Dermatol 16(2, Part 1): 267–291PubMedCrossRefGoogle Scholar
  55. 55.
    Weinstein GD (1996) Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. Br J Dermatol 135Suppl 49: 32–36PubMedCrossRefGoogle Scholar
  56. 56.
    Morimoto S, Kumahara Y (1985) A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3. Med J Osaka Univ 35(3–4): 51–54PubMedGoogle Scholar
  57. 57.
    Smith EL, Walworth NC, Holick MF (1986) Effect of 1 alpha,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 86(6): 709–714PubMedCrossRefGoogle Scholar
  58. 58.
    Kragballe K, Wildfang IL (1990) Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res 282(3): 164–167PubMedCrossRefGoogle Scholar
  59. 59.
    Kragballe K, Beck HI, Sogaard H (1988) Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind study. Br J Dermatol 119(2): 223–230PubMedCrossRefGoogle Scholar
  60. 60.
    Borel JF, Feurer C, Gubler HU, Stahelin H (1976) Biological effects of cyclosporin A: A new antilymphocytic agent. Agents Actions 6(4): 468–475PubMedCrossRefGoogle Scholar
  61. 61.
    Griffiths CE, Dubertret L, Ellis CN, Finlay AY, Finzi AF, Ho VC, Johnston A, Katsambas A, Lison AE, Naeyaert JM et al. (2004) Ciclosporin in psoriasis clinical practice: An international consensus statement. Br J Dermatol 150Suppl 67: 11–23PubMedCrossRefGoogle Scholar
  62. 62.
    Ellis CN, Krueger GG (2001) Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345(4): 248–255PubMedCrossRefGoogle Scholar
  63. 63.
    Kupper TS (2003) Immunologic targets in psoriasis. N Engl J Med 349(21): 1987–1990PubMedCrossRefGoogle Scholar
  64. 64.
    Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study Group (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349(21): 2014–2022PubMedCrossRefGoogle Scholar
  65. 65.
    Lebwohl MG (2005) Advances in psoriasis. Arch Dermatol 141(12): 1589–1590PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2008

Authors and Affiliations

  • Alissa Cowden
    • 1
  • Abby S. Van Voorhees
    • 1
  1. 1.University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations